Last Seven Days

27 articles from the last seven days

• 
  New indication sends revenue soaring

  An expanded PBS listing has been leapt upon by HCPs and patients, seeing reimbursements skyrocket

  10 Aug 2026
• 
  New Aussie Country Head tapped

  A meteoric rise to the top for this former MD who has gone from Franchise Head to Country Head in just 10 months

  10 Aug 2026
• 
  Company announces fresh layoffs

  A cost-saving program that started in 2023 has been extended again bringing more job cuts plus the other popular stories this week

  7 Aug 2026
• 
  Novartis expands two franchises

  The Swiss pharma giant has expanded its offerings in haematology and ophthalmology

  10 Aug 2026
• 
  $170M franchise safe for another year

  An injunction has prevented four drugs from facing first generic price cuts for at least another 12 months but the legal battle is far from over

  7 Aug 2026
• 
  Ex-J&J boss lands 5th Country Leader job

  Seasoned industry executive takes top job in expanding business with a growing portfolio of essential medicines

  6 Aug 2026
• 
  Diabetes drug restrictions dropped

  Big win for three companies with NZ's Pharmac extending access to diabetes treatments to a further 30,000 Kiwis

  6 Aug 2026
• 
  Pharma flags more job cuts

  An ongoing 'cost base realignment' has been extended with more global redundancies but the impact on the local team is unknown

  6 Aug 2026
• 
  21 Aussie Country Leaders exit in a year

  There has been a seismic shift in Country Leadership in Australia with 21 ANZ bosses departing in just 12 months

  10 Aug 2026
• 
  The pharmacy of unavailable drugs

  A powerful experience of being unable to access much-needed medicine is building public pressure for more drug funding

  5 Aug 2026
• 
  Aussie peanut drug on FDA fast track

  Melbourne company backed by the Novartis Future fund wins an FDA fast track for its peanut allergy immunotherapy

  6 Aug 2026
• 
  Who's moved to global HQ?

  Two leaders promoted to new roles, one landing a regional gig while the other has moved to international headquarters

  5 Aug 2026
• 
  Backlash over PBAC monitoring

  Pharma's unease with the PBAC's monitoring system of updated OS results of cancer drugs has been exposed in new documents

  5 Aug 2026
• 
  Deal paves way for global rollout

  Exclusive license agreement for new cancer drug worth up to $601.9 million and covering 66 countries, including Australia

  4 Aug 2026
• 
  Who's jumped ship to be first CMO?

  A pharma filling its first Chief Medical Officer position has landed an industry veteran with extensive experience in launching new indications

  10 Aug 2026
• 
  $300M blockbuster falls off patent

  First time generic competition for half a dozen drugs, including a top seller, ushers in painful statutory price reductions

  4 Aug 2026
• 
  Great workplace, six years running

  CEO of the Australian business says the achievement belongs to the people who bring the company's values to life

  7 Aug 2026
• 
  Eight pharmas win PBS listings

  A wave of PBS listings for August with more than half covering new medicines including the first new treatment option in 20 years

  3 Aug 2026
• 
  Where will this exec land next?

  ICYMI: Where is he going? J&J leader hush-hush on next move plus the other most popular stories this week

  31 Jul 2026
• 
  Who's keeping an eye on rival Reps?

  New service reveals which HCPs have interacted with competitor sales reps and it could be heading Down Under

  5 Aug 2026